Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Molecular characterization of non-B HIV type 1 isolates from patients of a department of infectious diseases, University Hospital of Bordeaux, France, 1989-2009.

Javaugue FC, Recordon-Pinson P, Decoin M, Masquelier B, Cazanave C, Neau D, Dupon M, Ragnaud JM, Fleury HJ.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1124-30. doi: 10.1089/AID.2011.0321. Epub 2012 Feb 17.

PMID:
22129096
2.

Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability.

Préau M, Protopopescu C, Raffi F, Rey D, Chêne G, Marcellin F, Perronne C, Ragnaud JM, Leport C, Spire B; Anrs Co8 Aproco-Copilote Study Group.

AIDS Care. 2012;24(4):434-43. doi: 10.1080/09540121.2011.613909. Epub 2011 Oct 14.

PMID:
21999644
3.

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.

Trimoulet P, Belzunce C, Faure M, Wittkop L, Reigadas S, Dupon M, Ragnaud JM, Fleury H, Neau D.

HIV Med. 2011 Sep;12(8):506-9. doi: 10.1111/j.1468-1293.2011.00913.x. Epub 2011 Mar 16.

4.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.

Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D; ANRS 116 SALTO Study Group.

J Med Virol. 2010 Nov;82(11):1819-28. doi: 10.1002/jmv.21907.

PMID:
20872707
5.

Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.

Breilh D, Djabarouti S, Trimoulet P, Le Bail B, Dupon M, Ragnaud JM, Fleury H, Saux MC, Thiébaut R, Chêne G, Neau D.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):428-30. doi: 10.1097/QAI.0b013e3181b62858. No abstract available.

PMID:
19858925
6.

Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort.

Neau D, Trimoulet P, Pereira E, Lafon ME, Gervais A, Ragnaud JM, Dupon M, Ecobichon JL, Chêne G, Raffi F; ANRS CO8 APROCO-COPILOTE Study Group.

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):227-9. doi: 10.1097/QAI.0b013e31816d9cc3. No abstract available.

PMID:
18520685
7.

Dual infection by chikungunya virus and other imported infectious agent in a traveller returning from India.

Ezzedine K, Cazanave C, Pistone T, Receveur MC, Neau D, Ragnaud JM, Malvy D.

Travel Med Infect Dis. 2008 May;6(3):152-4. doi: 10.1016/j.tmaid.2008.02.002. Epub 2008 Mar 25.

PMID:
18486073
8.

Prevalence and predictors of deterioration of a trustful patient-provider relationship among HIV-infected persons treated with antiretroviral therapy.

Préau M, Leport C, Villes V, Michelet C, Collin F, Carrieri MP, Ragnaud JM, Taieb A, Raffi F, Spire B; ANRS CO-8 APROCO Study Group.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):467-71.

PMID:
18434958
9.

Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004.

Trimoulet P, Boutonnet M, Winnock M, Faure M, Loko MA, De Lédinghen V, Bernard PH, Castéra L, Foucher J, Dupon M, Ragnaud JM, Lafon ME, Couzigou P, Dabis F, Fleury H, Neau D.

Gastroenterol Clin Biol. 2007 Dec;31(12):1088-94.

10.

Drug-drug interactions with systemic antifungals in clinical practice.

Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galpérine T, Abouelfath A, Valentino R, Dupon M, Hébert G, Moore N.

Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1227-33.

PMID:
17879355
11.

Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort.

Peuchant O, Capdepont S, Ragnaud JM, Aurillac-Lavignolle V, Thiébaut R, Fleury H, Masquelier B; ANRS CO3 Aquitaine Cohort.

Antivir Ther. 2007;12(4):559-62.

PMID:
17668565
12.

Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort.

Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, Ragnaud JM, Viallard JF, Dabis F, Chene G; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).

AIDS Patient Care STDS. 2007 Jul;21(7):458-68.

PMID:
17651027
13.

Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort.

Neau D, Winnock M, Castéra L, Bail BL, Loko MA, Géraut L, Dupon M, Ragnaud JM, Lacoste D, Lafon ME, Bioulac-Sage P, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):168-73.

PMID:
17527092
14.

Streptococcus canis infections in humans: retrospective study of 54 patients.

Galpérine T, Cazorla C, Blanchard E, Boineau F, Ragnaud JM, Neau D.

J Infect. 2007 Jul;55(1):23-6. Epub 2007 Feb 21.

PMID:
17320186
15.

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.

Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.

Antivir Ther. 2006;11(6):827-30.

PMID:
17310827
16.

Intermittent antiretroviral therapy in patients with controlled HIV infection.

Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, May T, Ragnaud JM, Aboulker JP, Molina JM; ANRS 106 Study team.

AIDS. 2007 Feb 19;21(4):457-66.

PMID:
17301564
17.

[A case of severe community acquired pneumonia and non-respiratory illness induced by Influenza A].

Duffau P, Moiton MP, Lafon ME, Braun C, Neau D, Ragnaud JM.

Med Mal Infect. 2006 Sep;36(9):473-5. Epub 2006 Oct 4. French.

PMID:
17027214
18.

HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.

Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H, Masquelier B.

HIV Med. 2006 Jul;7(5):294-8.

19.

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.

Antivir Ther. 2006;11(4):421-9.

PMID:
16856615
20.

[Clinical, microbiological, and therapeutic aspects of Nocardia sp. infections in the Bordeaux hospital from 1993 to 2003].

Moiton MP, Robert D, Bébéar CM, Neau D, Dugué C, Ragnaud JM.

Med Mal Infect. 2006 May;36(5):264-9. Epub 2006 Jun 9. French.

PMID:
16762519
21.

Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus.

Jouvencel AC, Neau D, Faure M, Neau M, Martinaud C, Legrand E, Trimoulet P, Garrigue I, Le Bail B, Bioulac-Sage P, Dupon M, Ragnaud JM, Fleury H, Lafon ME.

J Clin Microbiol. 2006 May;44(5):1877-80.

22.

Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases.

Vital C, Vital A, Canron MH, Jaffré A, Viallard JF, Ragnaud JM, Brechenmacher C, Lagueny A.

J Peripher Nerv Syst. 2006 Mar;11(1):20-9. Review.

PMID:
16519779
23.

An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.

Capdepont S, Aurillac-Lavignolle V, Faure M, Dupon M, Morlat P, Ragnaud JM, Chêne G, Fleury H, Masquelier B; GECSA.

J Clin Virol. 2006 May;36(1):36-42. Epub 2006 Feb 28.

PMID:
16513416
24.

Neuro-muscular biopsy in Churg-Strauss syndrome: 24 cases.

Vital A, Vital C, Viallard JF, Ragnaud JM, Canron MH, Lagueny A.

J Neuropathol Exp Neurol. 2006 Feb;65(2):187-92.

PMID:
16462209
25.

An imported case of canine rabies in Aquitaine: investigation and management of the contacts at risk, August 2004-March 2005.

Servas V, Mailles A, Neau D, Castor C, Manetti A, Fouquet E, Ragnaud JM, Bourhy H, Paty MC, Melik N, Astoul J, Cliquet F, Moiton MP, François C, Coustillas M, Minet JC, Parriaud P, Capek I, Filleul L.

Euro Surveill. 2005 Nov;10(11):222-5.

PMID:
16371687
26.

Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures.

Boucher S, Recordon-Pinson P, Neau D, Ragnaud JM, Titier K, Faure M, Fleury H, Masquelier B.

J Clin Virol. 2005 Dec;34(4):288-94.

PMID:
16286052
27.

Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients.

Mercié P, Thiébaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Cipriano C, Neau D, Morlat P, Ragnaud JM, Dupon M, Bonnet F, Lawson-Ayayi S, Malvy D, Roudaut R, Dabis F; Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA).

HIV Med. 2005 Nov;6(6):380-7.

28.

An imported case of canine rabies in Aquitaine: Investigation and management of the contacts at risk, August 2004-March 2005.

Servas V, Mailles A, Neau D, Castor C, Manetti A, Fouquet E, Ragnaud JM, Bourhy H, Paty MC, Melik N, Astoul J, Cliquet F, Moiton MP, François C, Coustillas M, Minet JC, Parriaud P, Capek I, Filleul L.

Euro Surveill. 2005 Nov;10(11):9-10. doi: 10.2807/esm.10.11.00578-en.

PMID:
29208098
29.

Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France.

Lawson-Ayayi S, Bonnet F, Bernardin E, Ragnaud JM, Lacoste D, Malvy D, Blaizeau MJ, Miremont-Salamé G, Dupon M, Mercié P, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

Clin Infect Dis. 2005 Apr 15;40(8):1188-93. Epub 2005 Mar 18.

PMID:
15791521
30.

Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003.

Neau D, Winnock M, Jouvencel AC, Faure M, Castéra L, Legrand E, Lacoste D, Ragnaud JM, Dupon M, Fleury H, Lafon ME, Dabis F; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine.

Clin Infect Dis. 2005 Mar 1;40(5):750-3. Epub 2005 Jan 28.

PMID:
15714424
31.

Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002).

Martin K, Lawson-Ayayi S, Miremont-Salamé G, Blaizeau MJ, Balestre E, Lacoste D, Ragnaud JM, Malvy D, Dupon M, Mercié P, Schaeverbeke T, Haramburu F, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

HIV Med. 2004 Nov;5(6):421-6.

32.

Emphysematous cystitis.

Perlemoine C, Neau D, Ragnaud JM, Gin H, Sahnoun A, Pariente JL, Rigalleau V.

Diabetes Metab. 2004 Sep;30(4):377-9.

PMID:
15525882
33.

[The risk of rabies in France and the illegal importation of animals from rabid endemic countries].

Galpérine T, Neau D, Moiton MP, Rotivel Y, Ragnaud JM.

Presse Med. 2004 Jul 10;33(12 Pt 1):791-2. French.

PMID:
15343094
34.

[Severe acute respiratory syndrome: one case of indirect transmission by Coronavirus].

Dutronc H, Dupon M, Cipriano G, Lafarie S, Lafon ME, Fleury HJ, Bocquentin F, Neau D, Ragnaud JM.

Rev Med Interne. 2004 Aug;25(8):607-9. French. No abstract available.

PMID:
15276297
35.

Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients.

Neau D, Winnock M, Galpérine T, Jouvencel AC, Castéra L, Legrand E, Tranchant E, Balestre E, Lacoste D, Ragnaud JM, Dupon M, Lafon ME, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2004 May;5(3):171-3.

36.

Cold bone defect on granulocytes labelled with technetium-99m-HMPAO scintigraphy: significance and usefulness for diagnosis and follow-up of osteoarticular infections.

Galpérine T, Dutronc H, Lafarie S, Neau D, Mérino B, Cipriano G, Ragnaud JM, Fernandez P, Basse-Cathalinat B, Dupon M.

Scand J Infect Dis. 2004;36(3):209-12.

PMID:
15119367
37.

Borna disease virus RNA in immunocompromised patients in southwestern France.

Cotto E, Neau D, Cransac-Neau M, Auriacombe M, Pellegrin JL, Ragnaud JM, Fillet AM, Belnard M, Fleury H, Lafon ME.

J Clin Microbiol. 2003 Dec;41(12):5577-81.

38.

[Menstrual staphylococcal toxic shock is still a reality].

Galpérine T, Neau D, Lina G, Richez C, Cazeau AL, Dutronc H, Dupon M, Ragnaud JM.

Presse Med. 2003 Jul 12;32(24):1121-2. French.

PMID:
12947741
39.

Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients.

Neau D, Jouvencel AC, Legrand E, Trimoulet P, Galperine T, Chitty I, Ventura M, Le Bail B, Morlat P, Lacut JY, Ragnaud JM, Dupon M, Fleury H, Lafon ME.

J Med Virol. 2003 Sep;71(1):41-8.

PMID:
12858407
40.

Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.

Neau D, Trimoulet P, Winnock M, Rullier A, Le Bail B, Lacoste D, Ragnaud JM, Bioulac-Sage P, Lafon ME, Chêne G, Dupon M; ROCO Study Group.

Clin Infect Dis. 2003 Jun 15;36(12):1564-71. Epub 2003 Jun 3.

PMID:
12802757
41.

T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.

Neau D, Galpérine T, Legrand E, Pitard V, Neau-Cransac M, Moreau JF, Ragnaud JM, Dupon M, Fleury H, Lafon ME.

HIV Med. 2003 Apr;4(2):120-6.

42.

Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

Pellegrin I, Caumont A, Garrigue I, Merel P, Schrive MH, Fleury H, Dupon M, Pellegrin JL, Ragnaud JM.

J Infect Dis. 2003 Jan 1;187(1):38-46. Epub 2002 Dec 13.

PMID:
12508144
43.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine.

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.

44.

CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.

Legrand E, Neau D, Galperine T, Trimoulet P, Moreau JF, Pitard V, Lacut JY, Ragnaud JM, Dupon M, Le Bail B, Bernard N, Schvoerer E, Houghton M, Fleury H, Lafon ME.

J Infect Dis. 2002 Aug 1;186(3):302-11. Epub 2002 Jul 17.

PMID:
12134226
45.

Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement.

Mercié P, Thiébaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Morlat P, Ragnaud JM, Dupon M, Malvy D, Bellet H, Lawson-Ayayi S, Roudaut R, Dabis F.

Ann Med. 2002;34(1):55-63.

PMID:
12014436
46.

Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection.

Trimoulet P, Neau D, Le Bail B, Rullier A, Winnock M, Galperine T, Legrand E, Schvoerer E, Dupon M, Ragnaud JM, Bioulac-Sage P, Chêne G, Fleury H, Lafon ME.

J Med Virol. 2002 Jun;67(2):143-51.

PMID:
11992575
47.

Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.

Savès M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chêne G; Antiprotéases Cohorte (APROCO) Study Group.

Clin Infect Dis. 2002 May 15;34(10):1396-405. Epub 2002 Apr 22.

PMID:
11981737
48.

Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.

Masquelier B, Neau D, Chêne G, Larbère J, Birac V, Ragnaud JM, Fleury HJ.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):309-12.

PMID:
11707665
49.

[Ecthyma gangrenosum caused by Pseudomonas aeruginosa without septicemia in a neutropenic patient].

Versapuech J, Léauté-Labrèze C, Thedenat B, Taieb A, Ragnaud JM.

Rev Med Interne. 2001 Sep;22(9):877-80. French.

PMID:
11599190
50.

Wild-mushroom intoxication as a cause of rhabdomyolysis.

Bedry R, Baudrimont I, Deffieux G, Creppy EE, Pomies JP, Ragnaud JM, Dupon M, Neau D, Gabinski C, De Witte S, Chapalain JC, Godeau P, Beylot J.

N Engl J Med. 2001 Sep 13;345(11):798-802. No abstract available.

Supplemental Content

Loading ...
Support Center